All Updates

All Updates

icon
Filter
Funding
Dantari raises USD 47 million in Series A funding round
Precision Medicine
Dec 8, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Dec 8, 2022

Dantari raises USD 47 million in Series A funding round

Funding

  • Biotechnology company Dantari raised USD 47 million in a Series A funding round led by Westlake Village BioPartners, along with participation from other venture capital firms and individual investors. 

  • The funds will be used to further the development of the company’s differentiated antibody-drug conjugate (ADC) and chemotherapeutic platforms. 

  • Post-funding the company also announced its appointment of Richard Markus as president and CEO, and its board of directors would be chaired by Sean Harper a co-founding managing director at Westlake.

  • California-based Dantari is a biotechnology company that focuses on developing treatments for cancers along with other diseases. The company’s chemotherapeutic candidate, DAN-22, is being developed using ADC and Targeted High-capacity Drug Conjugate technology originating from Caltech and is in Phase 1/2 trial for HER2-negative breast cancer. The company also has another candidate, DAN311, slated for human testing in 2023. Dantari’s candidates are being developed to use a variety of delivery systems, with its trials being currently carried out.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.